{"id":60221,"date":"2024-02-28T06:39:05","date_gmt":"2024-02-28T06:39:05","guid":{"rendered":"https:\/\/medsname.com\/primaquine\/"},"modified":"2026-04-30T10:23:49","modified_gmt":"2026-04-30T10:23:49","slug":"primaquine","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/primaquine\/","title":{"rendered":"Primaquine"},"content":{"rendered":"

<\/p>\n

\n

\u0393\u03c1\u03ae\u03b3\u03bf\u03c1\u03b7 \u03b1\u03c0\u03ac\u03bd\u03c4\u03b7\u03c3\u03b7<\/h3>\n

Primaquine<\/strong> \u03c0\u03b5\u03c1\u03b9\u03ad\u03c7\u03b5\u03b9 primaquine phosphate 15 mg base<\/strong> (Sanofi India). It is the only widely-stocked drug capable of radical cure of P. vivax and P. ovale relapsing malaria<\/strong> \u2014 it kills the dormant hypnozoite<\/em> liver stage that other antimalarials do not touch. Standard regimen: 30 mg base\/day for 14 days<\/strong> after a 3-day course of chloroquine has cleared the blood stage. Also used for P. falciparum<\/em> gametocyte clearance (single 0.25 mg\/kg dose, transmission-blocking) and as an option for Pneumocystis jirovecii<\/em> pneumonia in sulfa-allergic patients (with clindamycin). \u03a5\u03c0\u03bf\u03c7\u03c1\u03b5\u03c9\u03c4\u03b9\u03ba\u03ae \u03b5\u03be\u03ad\u03c4\u03b1\u03c3\u03b7 G6PD \u03c0\u03c1\u03b9\u03bd \u03b1\u03c0\u03cc \u03c4\u03b7 \u03c7\u03c1\u03ae\u03c3\u03b7<\/strong> \u2014 primaquine causes severe haemolytic anaemia in G6PD-deficient patients. Take with food to reduce GI upset.<\/p>\n<\/div>\n

\ud83c\udfed WHO-GMP certified manufacturer<\/strong>  \u00b7  \ud83d\udce6 Discreet packaging<\/strong>  \u00b7  \ud83c\udf0d Worldwide shipping<\/strong>  \u00b7  \u2b50 1,400+ \u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a><\/strong><\/div>\n

\ud83d\udee1\ufe0f Every order is covered by our \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 if your parcel does not arrive within 20 business days we ship a free replacement on EMS or ITPS courier.<\/p>\n

\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n

Primaquine is sourced from a WHO-GMP certified manufacturer and shipped worldwide in discreet packaging. Every order is backed by our \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/a> and supported by our 1,400+ \u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a>. Worldwide shipping with no prescription paperwork.<\/p>\n

About Primaquine<\/h2>\n

Primaquine is a 15 mg primaquine phosphate (base) tablet manufactured by Sanofi India under WHO-GMP certified conditions. Primaquine is an 8-aminoquinoline first developed by the US military in World War II. It is on the WHO Essential Medicines list and remains the only widely-available drug that kills the dormant hypnozoite liver stage of P. vivax<\/em> \u03ba\u03b1\u03b9 P. ovale<\/em> \u2014 without a primaquine course these parasites can relapse weeks to months after blood-stage treatment.<\/p>\n

How primaquine works<\/h2>\n

Primaquine’s exact molecular target is incompletely characterised \u2014 the leading hypothesis is that one of its CYP2D6-generated metabolites generates reactive oxygen species and free radicals that damage the parasite mitochondrial membrane in the liver-stage hypnozoite. The same oxidative chemistry is what damages G6PD-deficient red blood cells (where reduced glutathione cannot regenerate to neutralise oxidative stress) \u2014 explaining the parallel between primaquine’s antiparasitic activity and its haemolytic toxicity.<\/p>\n

Primaquine has weak activity on blood-stage parasites \u2014 pair it with chloroquine (in chloroquine-sensitive vivax\/ovale areas) or with an artemisinin combination therapy to first clear the blood stage. Primaquine alone is NOT a treatment for acute symptomatic malaria.<\/p>\n

\u0395\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2 \u03ba\u03b1\u03b9 \u03b4\u03bf\u03c3\u03bf\u03bb\u03bf\u03b3\u03af\u03b1<\/h2>\n
\n\n\n\n\n\n\n\n\n\n\n
\u0395\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2<\/th>\nDose (in mg base)<\/th>\n\u03a3\u03b7\u03bc\u03b5\u03b9\u03ce\u03c3\u03b5\u03b9\u03c2<\/th>\n<\/tr>\n<\/thead>\n
P. vivax \/ P. ovale radical cure (G6PD-normal)<\/td>\n30 mg base\/day for 14 days<\/td>\nAfter blood-stage treatment with chloroquine (or ACT). Adherence to all 14 days is essential \u2014 premature stop is the commonest reason for relapse.<\/td>\n<\/tr>\n
P. vivax in tropical \/ Oceanian strains (Chesson-like, more relapse-prone)<\/td>\n30 mg base\/day for 14 days, sometimes extended to 21 days at specialist discretion<\/td>\nHigher cumulative dose for chloroquine-resistant or hypnozoite-rich strains.<\/td>\n<\/tr>\n
P. vivax radical cure (G6PD intermediate)<\/td>\n0.75 mg\/kg once weekly \u00d7 8 weeks<\/td>\nSpecialist-supervised. Requires haematology follow-up.<\/td>\n<\/tr>\n
P. falciparum gametocyte clearance (transmission-blocking, WHO low-dose)<\/td>\n0.25 mg\/kg single dose with ACT<\/td>\nEven in G6PD-deficient patients the haemolysis risk is low at this single dose.<\/td>\n<\/tr>\n
Pneumocystis jirovecii pneumonia (PJP) \u2014 alternative to TMP-SMX in sulfa allergy<\/td>\n30 mg base\/day with clindamycin 600 mg PO TID for 21 days<\/td>\nSpecialist HIV \/ immunocompromised host context.<\/td>\n<\/tr>\n
Paediatric vivax radical cure (\u2265 6 months, G6PD-normal)<\/td>\n0.5 mg\/kg\/day for 14 days (max 30 mg\/day)<\/td>\nTablet-splitting may be needed.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
G6PD red-box \u2014 mandatory before use.<\/strong> Primaquine causes severe acute haemolytic anaemia in G6PD-deficient patients. Test G6PD status before prescribing<\/strong>. The standard fluorescent spot test or quantitative assay is acceptable. Severe G6PD deficiency (< 30 % activity)<\/strong> \u2014 primaquine contraindicated; use tafenoquine (different 8-aminoquinoline, single-dose, also G6PD-restricted) or alternative strategy. Intermediate G6PD deficiency (heterozygous female 30\u201370 %)<\/strong> \u2014 case-by-case decision; some authorities use a modified weekly schedule (0.75 mg\/kg once weekly \u00d7 8 weeks) under haematology supervision. Severe haemolysis presents as dark \/ cola-coloured urine, jaundice, pallor, fatigue, dyspnoea \u2014 stop the drug immediately and seek medical evaluation. G6PD prevalence is 5\u201310 % in many African, Mediterranean, Indian, Middle-Eastern, and Southeast-Asian populations, and substantially higher in some sub-populations (up to 25 % in Sardinian or Kurdish men).<\/div>\n

\u03a0\u03b1\u03c1\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b5\u03c2<\/h2>\n